Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Obsidian Therapeutics Announces Novel OBX-115 Therapy for Advanced Melanoma Treatment
Obsidian Therapeutics announced that the U.S. FDA has granted Fast Track Designation for OBX-115. This innovative engineered tumour-derived autologous T-cell immunotherapy, also known as tumour-infiltrating lymphocyte (TIL)...
Pulse Biosciences Announces Novel Cellfx® NSPFA Cardiac Surgery System
Pulse Biosciences has announced a novel cellfx® nspfa cardiac surgery system for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF). ...
AusperBio Announces Breakthrough Therapy Status for AHB-137 in the Management of Chronic Hepatitis B
AusperBio Therapeutics and Ausper Biopharma have announced that their investigational drug, AHB-137, has received Breakthrough Therapy Designation (BTD) from the Centre for Drug Evaluation (CDE) of the National Medical Products...
Lilly Announces Groundbreaking Kisunla™ (donanemab-azbt) Injection for Early Symptomatic Alzheimer's Treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla™ (donanemab-azbt), a monthly intravenous treatment by Eli Lilly and Company for adults with early-stage Alzheimer’s disease, including mild cognitive impairment (MCI) and mild dementia...
Fresenius Launches Groundbreaking Tyenne® (tocilizumab-aazg) a Subcutaneous Formulation
Fresenius introduced Tyenne® (tocilizumab-aazg), the first FDA-approved tocilizumab biosimilar available in both intravenous (IV) and subcutaneous formulations....
Loma Linda University Health Launched Groundbreaking HEMGENIX Gene Therapy for Hemophilia
Loma Linda University Health's Centre provides HEMGENIX, the first gene therapy approved by the FDA for haemophilia B, along with next-generation gene therapy for haemophilia A. This advancement has the potential to significantly improve the lives of many children and adults affected by these conditions....
Aurion Biotech's AURN001 Receives Breakthrough Therapy and Regenerative Medicine Advanced Therapy Designations
Designation for AURN001 is an allogeneic cell therapy intended to treat corneal edema caused by corneal endothelial disease.The Breakthrough Therapy Designation is aimed at accelerating the development and review of treatments for serious conditions, particularly when there is preliminary evidence...
Niagen+ Announces U.S. FDA Approval of ChromaDex’s First Pharmaceutical-Grade Injectable Niagen®
ChromaDex has announced the launch of Niagen+, the first pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Approved by the U.S. FDA for compounding by 503B outsourcing facilities, this intravenous (IV) and injectable NRC will be available in shot and push forms exclusively at clinics with a prescription....
Epigenica Introduces New Epigenetics Platform and Pioneering ChIP-seq Kit for Comprehensive Genome Profiling
Epigenica has launched the EpiFinder™ Platform, incorporating its patented hmqChIP-seq technology for high-throughput, multiplexing ChIP-seq applications. The flagship product, EpiFinder Genome, is the first commercial kit that allows simultaneous profiling of up to eight markers...
U.S. FDA Grants Breakthrough Therapy Designation to Bayer’s BAY 2927088
Bayer announced that the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and the U.S. FDA have granted Breakthrough Therapy designation to BAY 2927088. This investigational drug is intended for adults with unresectable or metastatic non-small cell lung...
